Efavirenz

證據等級: L5

預測適應症: 3 個

Efavirenz: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) established for HIV-1 infection treatment (reflected consistently across the supporting literature, though not explicitly listed in this evidence pack). The TxGNN model predicts it may be relevant to Simian Immunodeficiency Virus (SIV) infection, but the supporting evidence base consists almost entirely of preclinical macaque-model studies (16 publications) and a single withdrawn, enrollment-zero trial, with no confirmed human clinical development for this specific indication.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (inferred from consistent literature context; not explicitly captured in `taiwan_regulatory` data)
Predicted New Indication	Simian immunodeficiency virus infection
TxGNN Prediction Score	99.80%
Evidence Level	L4 (preclinical/mechanistic studies only)
Norway Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (original_moa: [Data Gap]). Based on the supporting literature, efavirenz is a well-characterized NNRTI that inhibits HIV-1 reverse transcriptase, and its clinical use for HIV-1 infection is well established in the broader literature context accompanying this evidence pack.

The predicted indication, "simian immunodeficiency virus infection," is not a human disease — SIV is the macaque analog of HIV used to build the RT-SHIV chimeric virus model (SIV backbone with HIV-1 reverse transcriptase inserted) specifically so that HIV-targeted NNRTIs like efavirenz can be tested in nonhuman primates. Mechanistically, this is coherent: because efavirenz's target (HIV-1 RT) is deliberately engineered into the RT-SHIV virus, efavirenz is pharmacologically active against it. However, this represents a research/animal-model use case rather than a novel human therapeutic indication, and should not be interpreted as a new clinical repurposing opportunity in the conventional sense.

It is worth noting that the second-ranked prediction ("feline acquired immunodeficiency syndrome," i.e., FIV in cats) shows the same pattern — real efavirenz-containing HIV trials (e.g., ATRIPLA in NCT01263015) appear in the evidence set, but only because ATRIPLA is the human comparator drug in trials of unrelated investigational compounds (dolutegravir/GSK1349572), not because of an FIV-specific human study.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00863668	NA	Withdrawn	0	Study of HIV/SIV viral decay kinetics with integrase inhibitor raltegravir in nonhuman primate models; withdrawn with zero enrollment, providing no usable efficacy data for efavirenz specifically

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35856680	2022	Preclinical (NHP model)	Antimicrob Agents Chemother	Mass spectrometry imaging of antiretroviral (incl. efavirenz) tissue distribution vs. viral RNA and fibrosis in RT-SHIV-infected macaque spleens
24777106	2014	Preclinical (NHP model)	Antimicrob Agents Chemother	Enhanced 4–5 drug HAART regimens improve RT-SHIV viral decay kinetics in rhesus macaques
24505452	2014	Preclinical (NHP model)	PLoS One	Characterizes residual viremia and lack of viral evolution in RT-SHIV macaque HAART model
26559632	2015	Preclinical (NHP model)	Retrovirology	Well-mixed plasma/tissue viral populations in RT-SHIV macaques suggest no ongoing tissue replication during ART
22933296	2012	Preclinical (NHP model)	J Virol	Ultrasensitive PCR detects pre-existing drug-resistant RT-SHIV variants in macaques prior to ART
21084490	2011	Preclinical (NHP model)	J Virol	Genetic diversity of RT-SHIV persists in macaques despite efavirenz-containing ART
21289110	2011	Preclinical (mechanistic)	J Virol	Gag-Pol/clathrin interaction study in HIV-1 and related primate lentiviruses
20032180	2010	Preclinical (NHP model)	J Virol	Identifies viral sanctuaries persisting during HAART in the RT-SHIV macaque AIDS model
20668516	2010	Preclinical (NHP model)	PLoS One	Viral decay kinetics characterized in HAART-treated RT-SHIV macaque model
19889213	2009	Preclinical (NHP model)	Retrovirology	RT-SHIV subpopulation dynamics in macaques during short-course efavirenz monotherapy followed by combination ART

Additional publications (e.g., PMID 15328115, 15564466, 15919889, 19195672, 15040537, 17045247) further support the RT-SHIV/efavirenz macaque model but are omitted here for brevity.

Norway Market Information

No marketing authorization data is available — efavirenz is currently not marketed in this jurisdiction (total_licenses: 0).

Safety Considerations

Please refer to the package insert for safety information. (All safety fields in this evidence pack — key warnings, contraindications, and drug interactions — are currently data gaps.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication ("simian immunodeficiency virus infection") is an animal-model disease rather than a human clinical indication, and the sole associated clinical trial was withdrawn with zero enrollment. Evidence Level L4 (preclinical only), combined with a Blocking data gap on TFDA/label safety information and missing MOA data, means this candidate is not ready for further evaluation.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain official label warnings/contraindications before any S1 safety screening
Resolve DG002: obtain formal MOA data from DrugBank to support mechanistic rationale
Clarify the actual human-relevant indication being targeted — the current "SIV infection" and "feline AIDS" predictions reflect nonhuman research models, not repurposable human diseases; re-run or re-map TxGNN output against a human-disease ontology filter
Confirm real-world marketing/regulatory status, since 0 authorizations are currently on file
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.